Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort

M.C. Postorino; M. Prosperi; E. Quiros-Roldan; F. Maggiolo; S. Di Giambenedetto; A. Saracino; S. Costarelli; S. Lorenzotti; L. Sighinolfi; M. Di Pietro; C. Torti

doi:10.1016/j.cmi.2014.10.022

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort

By M.C. Postorino, M. Prosperi, E. Quiros-Roldan, F. Maggiolo, S. Di Giambenedetto, A. Saracino, S. Costarelli, S. Lorenzotti, L. Sighinolfi, M. Di Pietro and C. Torti

Publisher: 'Elsevier BV'

Year: 2014

DOI identifier: 10.1016/j.cmi.2014.10.022

OAI identifier:

Provided by: MUCC (Crossref)

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

https://doi.org/10.1016/j.cmi.... (external link)

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort

Suggested articles